Protagonist Therapeutics
PTGX
137 hedge funds and large institutions have $522M invested in Protagonist Therapeutics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 42 reducing their positions, and 15 closing their positions.
300% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $2.59M
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
31% more capital invested
Capital invested by funds: $398M → $522M (+$124M)
21% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 42
5% more funds holding
Funds holding: 130 → 137 (+7)
3.18% more ownership
Funds ownership: 96.17% → 99.36% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.6M |
| 2 |
Millennium Management
New York
|
+$9.68M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.35M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$5.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.46M |
| 4 |
RI
RTW Investments
New York
|
-$4.93M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.19M |
PTGX Hedge Fund Activity: Q4 2022 in Review
137 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2022, worth a combined $522M — up 31% from $398M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PTGX positions and 15 closed out — a net gain of 8 holders — while 51 added to existing stakes and 42 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $12.6M. The largest seller was Fidelity Investments, cutting an estimated $23.1M.
- 137 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2022, up from 130 in Q3 2022.
- Funds reported $522M of Protagonist Therapeutics stock for Q4 2022, up 31% quarter-over-quarter.
- 23 funds opened new Protagonist Therapeutics positions in Q4 2022 and 15 closed out, a net change of +8 holders.
- The largest Protagonist Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $12.6M added.
- The largest Protagonist Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $23.1M sold.
Based on aggregated 13F filings for Q4 2022.